BioMarin Pharmaceutical Receives CRL from FDA, Sarepta Therapeutics Surges

January 14, 2016 5:00 PM

22 0

BioMarin Pharmaceutical Receives CRL from FDA, Sarepta Therapeutics Surges

BioMarin announced that it has received FDA’s CRL for Kyndrisa; stock of its competitor, Sarepta, surged

BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) disclosed that the Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) with regard to its New Drug Application (NDA) for Kyndrisa. The drug is used to treat Duchenne muscular dystrophy amenable to exon 51 skipping.

Also read: EU regulator accepts Sanofi/Regeneron's Dupixent product for review

Read more

To category page

Loading...